Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Short-Course Levofloxacin in Community-Acquired Pneumonia
NCT00236821Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Mar 2001
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial of levofloxacin in community acquired pneumonia (CAP) (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Clinical response rates based on signs and symptoms. Started Mar 2001; status: completed.
02
Drugs
levofloxacin
03
Conditions
community acquired pneumonia (CAP)
Beyond the preview
Go deeper on NCT00236821.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00236821.